Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Similar articles for PubMed (Select 21926271)

1.

Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies.

Serreze DV, Chapman HD, Niens M, Dunn R, Kehry MR, Driver JP, Haller M, Wasserfall C, Atkinson MA.

Diabetes. 2011 Nov;60(11):2914-21. doi: 10.2337/db11-0705. Epub 2011 Sep 16.

2.

Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets.

von Büdingen HC, Palanichamy A, Lehmann-Horn K, Michel BA, Zamvil SS.

Eur Neurol. 2015;73(3-4):238-46. doi: 10.1159/000377675. Epub 2015 Mar 25.

3.

B-cell inhibition by cross-linking CD79b is superior to B-cell depletion with anti-CD20 antibodies in treating murine collagen-induced arthritis.

Brühl H, Cihak J, Talke Y, Rodriguez Gomez M, Hermann F, Goebel N, Renner K, Plachý J, Stangassinger M, Aschermann S, Nimmerjahn F, Mack M.

Eur J Immunol. 2015 Mar;45(3):705-15. doi: 10.1002/eji.201444971. Epub 2014 Dec 28.

PMID:
25471597
4.

Targeting B lymphocytes in progressive fibrosing mediastinitis.

Westerly BD, Johnson GB, Maldonado F, Utz JP, Specks U, Peikert T.

Am J Respir Crit Care Med. 2014 Nov 1;190(9):1069-71. doi: 10.1164/rccm.201407-1258LE. No abstract available.

PMID:
25360730
5.

Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity.

Lehmann-Horn K, Kinzel S, Feldmann L, Radelfahr F, Hemmer B, Traffehn S, Bernard CC, Stadelmann C, Brück W, Weber MS.

Ann Clin Transl Neurol. 2014 Jul;1(7):490-6. doi: 10.1002/acn3.71. Epub 2014 Jul 3.

6.

Role of B lymphocytes in the pathogenesis of type 1 diabetes.

Hinman RM, Cambier JC.

Curr Diab Rep. 2014;14(11):543. doi: 10.1007/s11892-014-0543-8. Review.

PMID:
25189436
7.

Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.

Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, Baranzini SE, Leppert D, von Büdingen HC.

J Immunol. 2014 Jul 15;193(2):580-6. doi: 10.4049/jimmunol.1400118. Epub 2014 Jun 13.

PMID:
24928997
8.

Anti-TCR mAb induces peripheral tolerance to alloantigens and delays islet allograft rejection in autoimmune diabetic NOD mice.

Deng R, Khattar M, Xie A, Schroder PM, He X, Chen W, Stepkowski SM.

Transplantation. 2014 Jun 27;97(12):1216-24. doi: 10.1097/TP.0000000000000120.

PMID:
24854475
9.

CD20+ B cell depletion in systemic autoimmune diseases: common mechanism of inhibition or disease-specific effect on humoral immunity?

Pateinakis P, Pyrpasopoulou A.

Biomed Res Int. 2014;2014:973609. doi: 10.1155/2014/973609. Epub 2014 Mar 27. Review.

10.

In vivo detection of peripherin-specific autoreactive B cells during type 1 diabetes pathogenesis.

Garabatos N, Alvarez R, Carrillo J, Carrascal J, Izquierdo C, Chapman HD, Presa M, Mora C, Serreze DV, Verdaguer J, Stratmann T.

J Immunol. 2014 Apr 1;192(7):3080-90. doi: 10.4049/jimmunol.1301053. Epub 2014 Mar 7.

11.

Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®).

Ryan AM, Sokolowski SA, Ng CK, Shirai N, Collinge M, Shen AC, Arrington J, Radi Z, Cummings TR, Ploch SA, Stephenson SA, Tripathi NK, Hurst SI, Finch GL, Leach MW.

Toxicol Pathol. 2014 Oct;42(7):1069-81. doi: 10.1177/0192623313520351. Epub 2014 Mar 6.

PMID:
24604381
12.

Plasmacytoid dendritic cells license regulatory T cells, upon iNKT-cell stimulation, to prevent autoimmune diabetes.

Beaudoin L, Diana J, Ghazarian L, Simoni Y, Boitard C, Lehuen A.

Eur J Immunol. 2014 May;44(5):1454-66. doi: 10.1002/eji.201343910. Epub 2014 Feb 27.

PMID:
24481989
13.

B cells and type 1 diabetes ...in mice and men.

Hinman RM, Smith MJ, Cambier JC.

Immunol Lett. 2014 Aug;160(2):128-32. doi: 10.1016/j.imlet.2014.01.010. Epub 2014 Jan 25. Review.

PMID:
24472603
14.

The need for markers and predictors of Rituximab treatment resistance.

Sitaru C, Thiel J.

Exp Dermatol. 2014 Apr;23(4):236-7. doi: 10.1111/exd.12331. Epub 2014 Feb 16.

PMID:
24450995
15.

BAFF regulates activation of self-reactive T cells through B-cell dependent mechanisms and mediates protection in NOD mice.

Mariño E, Walters SN, Villanueva JE, Richards JL, Mackay CR, Grey ST.

Eur J Immunol. 2014 Apr;44(4):983-93. doi: 10.1002/eji.201344186. Epub 2014 Feb 16.

PMID:
24435807
16.
17.

Rotavirus acceleration of murine type 1 diabetes is associated with increased MHC class I-restricted antigen presentation by B cells and elevated proinflammatory cytokine expression by T cells.

Pane JA, Webster NL, Zufferey C, Coulson BS.

Virus Res. 2014 Jan 22;179:73-84. doi: 10.1016/j.virusres.2013.11.009. Epub 2013 Nov 15.

PMID:
24246305
18.

B-cell-targeted therapy in adult glomerulonephritis.

Tanna A, Tam FW, Pusey CD.

Expert Opin Biol Ther. 2013 Dec;13(12):1691-706. doi: 10.1517/14712598.2013.851191. Epub 2013 Nov 5. Review.

PMID:
24188581
19.

B cells: depletion or functional modulation in rheumatic diseases.

Dörner T, Lipsky PE.

Curr Opin Rheumatol. 2014 Mar;26(2):228-36. doi: 10.1097/BOR.0000000000000000. Review.

PMID:
24126901
20.

B-lymphocyte depletion with rituximab and β-cell function: two-year results.

Pescovitz MD, Greenbaum CJ, Bundy B, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, Moran A, Raskin P, Rodriguez H, Schatz DA, Wherrett DK, Wilson DM, Krischer JP, Skyler JS; Type 1 Diabetes TrialNet Anti-CD20 Study Group.

Diabetes Care. 2014 Feb;37(2):453-9. doi: 10.2337/dc13-0626. Epub 2013 Sep 11.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk